December #42 : Nevirapine for Best Head - by Lark Lands, PhD

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

The Age of Ignorance

Reboot Your System

POZ Annual Givers Guide

POZ Annual Givers Guide, Part 2

A Happy Convert

Working Mom

Money Man

You Can Take It With You

LifeStyle Change

Mom Knows Best

Foul Ball

S.O.S

To the Editor

Knowledge=Power

Don't Ask, Do Tell?

In Your Wildest Steams

Boys in Green

When This You See

Ab-Fab Babs

Say What

POZarazzi: Random Harvest

Pirate of Penance

Show and Tell

hiv and Me

How Am I?

A Bite of the Apple

Down-and-Dirty Markups

Grow Your Own Bacteria

The Rx Files

Beyond Grapefruit Juice

Douching Dangers

Therapeutic Vaccine in the Works

A B.i.d. for Easier Adherence

Nevirapine for Best Head

Strong in the Tooth

Buyers Clubs

Where to Find It

Pair of Aces

Aunt Evelyn's Letters

POZ Picks

Letter from Sri Lanka: Island Fever

Wrong Way on the ADA

Mann of the Hour

Obits

Talk to the Hand



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

December 1998

Nevirapine for Best Head

by Lark Lands, PhD

The limited ability of most antiretrovirals to cross the blood-brain barrier (BBB, the fibrous bag that encloses the brain and spinal cord) has been a major obstacle to stopping the progressive loss of brain cells caused by HIV. But a new study has found that the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune) can penetrate the BBB far better than any other anti-HIV agent. That’s good news, since HIV’s effects on the central nervous system (CNS, the brain and spinal cord) cause neurological problems in about 20 percent of asymptomatic people and an alarming 70 percent to 90 percent of those with more advanced disease.

UCLA’s Michael Wool, MD, says that CNS damage may go unnoticed because “the brain can take a licking and keep on ticking.” Even when symptoms appear—whether minor memory problems and anxiety or more severe forms of thinking dysfunction, depression or mania—they often go unrecognized as HIV related.

One irony of the protease age is that CNS symptoms are increasing in frequency. Why? As PWAs live longer, the brain can become ever more damaged, since drugs that work well in the bloodstream may not in the CNS. That’s because the virus’ drug-resistance mutations may differ between blood and brain. Wool says, “I’ve seen people with undetectable blood levels whose HIV level in the brain is over a million.”

For this reason, Wool recommends always including a minimum of one and preferably two antiretrovirals known to reach the CNS well, adding: “For patients with neurologic problems, spinal fluid should be obtained for viral load and perhaps phenotypic [drug sensitivity] testing that can help guide therapy choices.” Based on research and clinical experience, he believes the best current CNS antiretroviral choices, in descending order of effectiveness, are nevirapine, AZT (Retrovir), d4T (Zerit), 3TC (Epivir) and abacavir (Ziagen).




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chipper52
    Palm Springs
    California


    TanyaB
    Delray Beach
    Florida


    pevans
    San Francisco
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.